Questcor Pharmaceuticals is a biopharmaceutical company focused on the treatment of patients with autoimmune and inflammatory disorders. Co.'s primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved for the treatment of 19 indications, including the treatment of exacerbations of multiple sclerosis in adults, as monotherapy for the treatment of infantile spasms in infants and children, and for several rheumatology related conditions. Co.'s other product is Doral® (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.
QCOR — Key Stats (updated Monday, March 3, 10:21 AM)
Thu, Mar 6, 12:37 PM, Zacks ArQule's Loss Narrows in Q4 - Analyst Blog ArQule reported a loss of 10 cents per share in the fourth quarter of 2013, narrower than the Zacks Consensus Estimate of a loss of 13 cents per share.
Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Service. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20
minutes; ETF data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.